Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 5/20 | 0.39 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29218664 | 0.85 | NR3C2 (0.50) | NR3C2ATMMAP3K7PIK3CAPIK3CB | |
| SCHEMBL17537345 | 0.82 | NR3C2 (0.47) | NR3C2PIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL12984271 | 0.81 | NR3C2 (0.49) | NR3C2PIK3CDPIK3CGMTORAKT1 | |
| SCHEMBL12983917 | 0.81 | NR3C2 (0.49) | NR3C2PIK3CDPIK3CGMTORAKT1 | |
| SCHEMBL18436950 | 0.81 | KMT2A (0.53) | ATMPRKDC | |
| SCHEMBL18436315 | 0.81 | KMT2A (0.53) | ATMPRKDC | |
| SCHEMBL2131669 | 0.79 | HTR3E (0.51) | NR3C2PIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL27777676 | 0.78 | HRH3 (0.55) | NR3C2 | |
| SCHEMBL17531163 | 0.77 | ALDH1A1 (0.50) | — | |
| SCHEMBL14376036 | 0.77 | NR3C2 (0.47) | NR3C2ATMMAP3K7LRRK2WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179181-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-28 | — | — | US | disclosed |
| US-9845309-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2017-12-19 | — | — | US | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-9452998-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | NR3C2 3714/4885ATM 362/4885MAP3K7 43/4885 |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | NR3C2 3714/4885ATM 362/4885MAP3K7 43/4885 |
| US-20180179181-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | NR3C2 3714/4885ATM 362/4885MAP3K7 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.